Year: 2025

Bekaert announces the next tranche of its Share Buyback Program Bekaert announces that it will start the next tranche of its buyback program on 21 November 2025, for a total consideration of up to € 25 million. It is intended that, subject to market conditions, this tranche will be completed prior to the release of the full year 2025 results, scheduled for 26 February 2026. During this period, Bekaert will regularly publish press releases with updates on the progress made, as required by law. This information will also be available on the investor relations pages of our website. As announced previously, all shares bought as part of the Program will be cancelled.  Attachmentp251121E – Bekaert announces the next tranche of its Share Buyback Program

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year end These agreements ensure BioAtla can maintain operational momentum while completing that processSAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with an affiliate of Yorkville Advisors Global (Yorkville) and funds managed by of Anson Advisors Inc. to provide an aggregate $7.5 million advance...

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional...

COLUMBUS, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced today the pricing of its previously announced underwritten public offering of depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of its Non-Cumulative Perpetual Preferred Stock, Series A, par value $0.01 per share (the “Series A Preferred Stock”), with a liquidation preference of $25 per Depositary Share (equivalent to $1,000 per share of Series A Preferred Stock). The Company expects to apply to list the Depositary Shares on The New York Stock Exchange. The closing of the offering of the Depositary Shares is expected to occur on November 25, 2025, subject to the satisfaction of customary closing conditions, and is expected to result in approximately...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class team VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has appointed Cadmus...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, Nov. 20, 2025 (GLOBE NEWSWIRE) — Montauk Metals Inc. (TSX-V: MTK) (the “Company” or “Montauk”) filed a corporate assignment into bankruptcy pursuant to the Bankruptcy and Insolvency Act (Canada) (the “BIA”). The filing comes after the Board was unable to reach a settlement with its creditors. The Fuller Landau Group Inc. has been appointed as the Licensed Insolvency Trustee (the “Trustee”) under the bankruptcy proceedings. Montauk’s three (3) directors and officers resigned immediately prior to the bankruptcy proceedings. All further matters will be handled by the Trustee. The Trustee will administer the process of distributing any realizable assets to proven creditors, which consist of cash balances which are less than...

AlphaTON Capital has No Equity Line Financing with ATW Partners or any other provider. ATW Partners is not an investor whatsoever. AlphaTON Capital has never drawn down the entire Bitgo facility and has continued to manage leverage at 7% Debt to Equity Ratio. New York, NY, Nov. 20, 2025 (GLOBE NEWSWIRE) — AlphaTON Capital Corp. (Nasdaq: ATON) (“AlphaTON” or the “Company”), a specialized digital asset technology company focused on the Telegram ecosystem, today issued a comprehensive update to shareholders regarding its balance sheet composition and strategic initiatives executed since the closing of its PIPE funding on September 25, 2025. The Company has aggressively deployed capital into high-conviction assets, establishing a robust foundation for long-term growth through a three-pillar strategy: Treasury Accumulation Network...

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs. Dr John Levine, Chair of the BMT CTN Steering...